Targeted Therapy of Severe Infections Caused by Staphylococcus aureus in Critically Ill Adult Patients: A Multidisciplinary Proposal of Therapeutic Algorithms Based on Real-World Evidence
Abstract:(1) Introduction: To develop evidence-based algorithms for targeted antibiotic therapy of infections caused by Staphylococcus aureus in critically ill adult patients. (2) Methods: A multidisciplinary team of four experts had several rounds of assessment for developing algorithms concerning targeted antimicrobial therapy of severe infections caused by Staphylococcus aureus in critically ill patients. The literature search was performed by a researcher on PubMed-MEDLINE (until August 2022) to provide evidence fo… Show more
“…However, it is possible to assert that the use of daptomycin in combination can be considered as standard of care in the context of IE (regardless of the species involved) [21] and in the treatment of viridans streptococci, since in these cases the risk of the emergence of resistance is sufficiently concrete. In other circumstances, combination therapy should be taken into consideration in case of difficult-to-treat infections [15,21,[50][51][52]57].…”
Section: Daptomycinmentioning
confidence: 99%
“…As already underlined, ceftaroline has been studied in combination with other anti-MRSA antibiotics (particularly daptomycin) for the treatment of BSI, including IE. This association has been proposed in order to increase the anti-bacterial efficacy and protect daptomycin from the emergence of resistance during treatment [15,21,51,52,57].…”
Section: Ceftarolinementioning
confidence: 99%
“…Another promising association is fosfomycin plus linezolid for the rescue therapy of severe VAP and CNS infections. These combinations may provide a synergistic antibacterial activity and reduce the risk of the emergence of resistance [15,19,146].…”
Section: Fosfomycinmentioning
confidence: 99%
“…The most relevant of these are daptomycin [8], dalbavancin [9], linezolid [10], tedizolid [11], ceftaroline [12], ceftobiprole [13], and fosfomycin [14]. The availability of these drugs allowed clinicians to limit the use of vancomycin, which is burdened by greater adverse effects and lower efficacy [15].…”
Antibiotic resistance in Gram-positive pathogens is a relevant concern, particularly in the hospital setting. Several antibiotics are now available to treat these drug-resistant pathogens, such as daptomycin, dalbavancin, linezolid, tedizolid, ceftaroline, ceftobiprole, and fosfomycin. However, antibiotic resistance can also affect these newer molecules. Overall, this is not a frequent phenomenon, but it is a growing concern in some settings and can compromise the effectiveness of these molecules, leaving few therapeutic options. We reviewed the available evidence about the epidemiology of antibiotic resistance to these antibiotics and the main molecular mechanisms of resistance, particularly methicillin-resistant Sthaphylococcus aureus, methicillin-resistant coagulase-negative staphylococci, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus pneumoniae. We discussed the interpretation of susceptibility tests when minimum inhibitory concentrations are not available. We focused on the risk of the emergence of resistance during treatment, particularly for daptomycin and fosfomycin, and we discussed the strategies that can be implemented to reduce this phenomenon, which can lead to clinical failure despite appropriate antibiotic treatment. The judicious use of antibiotics, epidemiological surveillance, and infection control measures is essential to preserving the efficacy of these drugs.
“…However, it is possible to assert that the use of daptomycin in combination can be considered as standard of care in the context of IE (regardless of the species involved) [21] and in the treatment of viridans streptococci, since in these cases the risk of the emergence of resistance is sufficiently concrete. In other circumstances, combination therapy should be taken into consideration in case of difficult-to-treat infections [15,21,[50][51][52]57].…”
Section: Daptomycinmentioning
confidence: 99%
“…As already underlined, ceftaroline has been studied in combination with other anti-MRSA antibiotics (particularly daptomycin) for the treatment of BSI, including IE. This association has been proposed in order to increase the anti-bacterial efficacy and protect daptomycin from the emergence of resistance during treatment [15,21,51,52,57].…”
Section: Ceftarolinementioning
confidence: 99%
“…Another promising association is fosfomycin plus linezolid for the rescue therapy of severe VAP and CNS infections. These combinations may provide a synergistic antibacterial activity and reduce the risk of the emergence of resistance [15,19,146].…”
Section: Fosfomycinmentioning
confidence: 99%
“…The most relevant of these are daptomycin [8], dalbavancin [9], linezolid [10], tedizolid [11], ceftaroline [12], ceftobiprole [13], and fosfomycin [14]. The availability of these drugs allowed clinicians to limit the use of vancomycin, which is burdened by greater adverse effects and lower efficacy [15].…”
Antibiotic resistance in Gram-positive pathogens is a relevant concern, particularly in the hospital setting. Several antibiotics are now available to treat these drug-resistant pathogens, such as daptomycin, dalbavancin, linezolid, tedizolid, ceftaroline, ceftobiprole, and fosfomycin. However, antibiotic resistance can also affect these newer molecules. Overall, this is not a frequent phenomenon, but it is a growing concern in some settings and can compromise the effectiveness of these molecules, leaving few therapeutic options. We reviewed the available evidence about the epidemiology of antibiotic resistance to these antibiotics and the main molecular mechanisms of resistance, particularly methicillin-resistant Sthaphylococcus aureus, methicillin-resistant coagulase-negative staphylococci, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus pneumoniae. We discussed the interpretation of susceptibility tests when minimum inhibitory concentrations are not available. We focused on the risk of the emergence of resistance during treatment, particularly for daptomycin and fosfomycin, and we discussed the strategies that can be implemented to reduce this phenomenon, which can lead to clinical failure despite appropriate antibiotic treatment. The judicious use of antibiotics, epidemiological surveillance, and infection control measures is essential to preserving the efficacy of these drugs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.